LOX-1 inhibition in ApoE KO mice using a schizophyllan-based antisense oligonucleotide therapy

Molecular Therapy Nucleic Acids

Volumn 1, Issue DEC, 2012, Pages e58-

  Amati, Francesca ^a   Diano, Laura ^a   Vecchione, Lucia ^a   Norata, Giuseppe Danilo ^b,c,d   Koyama, Yoshikazu ^e,f   Cutuli, Lucia ^b   Catapano, Alberico Luigi ^b,g   Romeo, Francesco ^a   Ando, Hironori ^f   Novelli, Giuseppe ^h,i,j  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c Società Italiana Studio Aterosclerosi   (Italy)

^d QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^e HOKKAI GAKUEN UNIVERSITY   (Japan)

^f NapaJen Pharma Inc ^*  (Japan)

^g IRCCS MULTIMEDICA   (Italy)

^h CENTRAL ARKANSAS VETERANS HEALTHCARE SYSTEM   (United States)

ⁱ FATEBENEFRATELLI HOSPITAL   (Italy)

^j Responsable for National Scientific Habilitation   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; APOLIPOPROTEIN E; OXIDIZED LOW DENSITY LIPOPROTEIN RECEPTOR 1; SCHIZOPHYLLAN;

ANTISENSE THERAPY; ATHEROSCLEROSIS; CELLS; DRUG DELIVERY SYSTEM; HEART MUSCLE CELL; HUMAN; INFLAMMATORY BOWEL DISEASE; LETTER; MACROPHAGE; NONHUMAN; PRIORITY JOURNAL; VASCULAR SMOOTH MUSCLE;

EID: 84880364919     PISSN: None     EISSN: 21622531     Source Type: Journal    
DOI: 10.1038/mtna.2012.45     Document Type: Letter

References (8)

1. Takedatsu, H, Mitsuyama, K, Mochizuki, S, Kobayashi, T, Sakurai, K, Takeda, H et al. (2012). A new therapeutic approach using a schizophyllan-based drug delivery system for inflammatory bowel disease. Mol Ther 20: 1234-1241.
2. Beytía, Mde L, Vry, J and Kirschner, J (2012). Drug treatment of Duchenne muscular dystrophy: available evidence and perspectives. Acta Myol 31: 4-8.
3. Aoyama, T, Sawamura, T, Furutani, Y, Matsuoka, R, Yoshid, MC, Fujiwara, H et al. (1999). Structure and chromosomal assignment of the human lectin-like oxidized low-densitylipoprotein receptor-1 (LOX-1) gene. Biochem J 339: 177-184. (Pubitemid 29179305)
4. Mehta, JL, Chen, J, Hermonat, PL, Romeo, F and Novelli, G (2006). Lectin-like, oxidized low-density lipoprotein receptor-1 (LOX-1): a critical player in the development of atherosclerosis and related disorders. Cardiovasc Res 69: 36-45. (Pubitemid 41814809)
5. Goyal, T, Mitra, S, Khaidakov, M, Wang, X, Singla, S, Ding, Z et al. (2012). Current concepts of the role of oxidized ldl receptors in atherosclerosis. Curr Atheroscler Rep 14: 150-159.
6. Yoshimoto, R, Fujita, Y, Kakino, A, Iwamoto, S, Takaya, T and Sawamura, T (2011). The discovery of LOX-1, its ligands and clinical significance. Cardiovasc Drugs Ther 25: 379-391.
7. Li, D and Mehta, JL (2000). Antisense to LOX-1 inhibits oxidized LDL-mediated upregulation of monocyte chemoattractant protein-1 and monocyte adhesion to human coronary artery endothelial cells. Circulation 101: 2889-2895. (Pubitemid 30415877)
8. Norata, GD, Marchesi, P, Pulakazhi Venu, VK, Pasqualini, F, Anselmo, A, Moalli, F et al. (2009). Deficiency of the long pentraxin PTX3 promotes vascular inflammation and atherosclerosis. Circulation 120: 699-708.